TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26928074
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with aluminum hydroxide
Study: 26928074
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with MF59(®)
Study: 22264496
Drug: Interview for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interview for Deterioration in Daily Living Activities in Dementia (IDDD)
Study: 18555114
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker verapamil (100 microg injected into renal artery)
Study: 16133638
Drug: Milk Basic
Normalized name: Milk Basic Protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk Basic Protein (MBP) 40 mg per day for 6 months
Study: 12234091
Drug: modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint-induced therapy (mCIT)
Study: 12234091
Drug: regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: regular therapy (TR)
Study: 12234091
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy (CON)
Study: 291771
Drug: Immunotherapy (BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (BCG and allogenic acute myelomonocytic leukemic cells)
Study: 26452709
Drug: Erythropoietin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (40,000 units subcutaneously once per week for a maximum of three doses)
Study: 26452709
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride subcutaneously once per week for a maximum of three doses)
Study: 22924372
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplements (1 gr daily for three months)
Study: 19180855
Drug: Suspension seat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension seat
Study: 17350342
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of antiepileptic drugs (AEDs)
Study: 15249567
Drug: Emtricitabine 200
Normalized name: emtricitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine 200 mg once daily (plus stavudine placebo twice daily) (n = 286)
Study: 15249567
Drug: Stavudine at
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n = 285)
Study: 3551551
Drug: Lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 1 mg for 7 nights
Study: 3551551
Drug: Chlormethiazole 384
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole 384 mg for 7 nights
Study: 27845635
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of daily isoniazid preventive therapy (IPT)
Study: 20697947
Drug: Conventional integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional integrative medicine
Study: 10417749
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel 100 microg/g once daily
Study: 10417749
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel 300 microg/g once daily
Study: 10417749
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel 100 microg/g twice daily
Study: 10417749
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (sodium carboxymethylcellulose)
Study: 7496281
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (6 to 16 sessions)
Study: 2107830
Drug: L‐carnitine supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐carnitine supplemented formula (600 nmol/ml, for 7 days)
Study: 25533009
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-carnitine supplementation)
Study: 540521
Drug: Xanthinol nicotinate
Normalized name: xanthinol
DrugBank: Xanthinol (DB09092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthinol nicotinate (2400 mg daily for 10 weeks)
Study: 540521
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 tablets daily for 10 weeks)
Study: 23537458
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg
Study: 29971469
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E vaginal suppository
Study: 28019010
Drug: Selumetinib 50
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 50 mg (renal impairment study)
Study: 28019010
Drug: Selumetinib (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (20-50 mg depending on liver dysfunction) (hepatic impairment study)
Study: 21479690
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (IA)
Study: 19817194
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy and horizontal bar exercise
Study: 17710800
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and yixin jiangya Capsules
Study: 15125121
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of nasal salmon calcitonin daily for three months
Study: 7512100
Drug: Alprazolam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (6 to 10 mg/day for 43 days)
Study: 29714449
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MF) for 4 weeks
Study: 27333970
Drug: AP with
Normalized name: Unicap with Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP with exercise dosing adjustment (APX)
Study: 27333970
Drug: AP with
Normalized name: Unicap with Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP with no exercise dosing adjustment (APN)
Study: 27333970
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy (SAP)
Study: 25042878
Drug: Cetuximab +
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab + chemoradiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel
Study: 19967577
Drug: No-treatment wait-list
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment wait-list control
Study: 28732480
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g b.d.)
Study: 17327307
Drug: Higher-dose oral
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose oral contraceptive (OCP) 35 microg ethinyl estradiol [EE]/2 mg cyproterone acetate
Study: 17327307
Drug: Low-dose OCP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OCP (20 microg EE/100 microg levonorgestrel + aldactone 50 mg b.d.)
Study: 16713435
Drug: Simvastatin, 80
Normalized name: Simvastatin, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 80 mg/d
Study: 8608881
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily after H. pylori eradication
Study: 8608881
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily before H. pylori eradication
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 60 mg
Study: 7075499
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 80 mg
Study: 15374410
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 100 mg
Study: 2931964
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg t.i.d. for 3 months)
Study: 2412051
Drug: Ketanserin (subacute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (subacute treatment)
Study: 23392075
Drug: Bendamustine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine with 500 mL of diluent
Study: 23392075
Drug: Bendamustine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine with 250 mL of diluent
Study: 23392075
Drug: Bendamustine concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine concentration ≤0.40 mg/mL
Study: 23392075
Drug: Bendamustine concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine concentration 0.41-0.60 mg/mL
Study: 23392075
Drug: Bendamustine concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine concentration >0.60 mg/mL
Study: 19325050
Drug: Oil-on-top treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-on-top treatment (OT): 4 g of high-oleic-acid rapeseed oil (4.6 ml, 36 kcal) infused after a fat-free liquid meal (LM, 325 ml, 145 kcal)
Study: 19325050
Drug: Emulsion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion treatment (EM): 4 g of labeled rapeseed oil incorporated into LM (325 ml, 181 kcal); 4.6 ml of saline infused as control
Study: 17229483
Drug: SPA therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPA therapy (ST)
Study: 9149172
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute and intermittent vocalization
Study: 9149172
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute
Study: 9149172
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer therapy with deep and slow inhalation at a respiratory rate of 12 breaths/minute
Study: 31848062
Drug: Inhaled N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled N-acetylcysteine (NAC) with oral rabeprazole
Study: 31848062
Drug: Oral rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rabeprazole
Study: 27114389
Drug: Insulin users
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin users in ILI
Study: 27114389
Drug: Non-insulin users
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin users in ILI
Study: 22735384
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice daily, orally)
Study: 22735384
Drug: Dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1000 mg/m(2) intravenously every 3 weeks)
Study: 20721651
Drug: Probiotic bacterial
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic bacterial formulation (90 billion CFUs/day)
Study: 15629973
Drug: Infloran (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infloran (Lactobacillus acidophilus and Bifidobacterium infantis) with breast milk twice daily until discharged
Study: 11956264
Drug: Sequential biochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential biochemotherapy (CVD + interleukin‐2 + interferon alfa‐2b)
Study: 11956264
Drug: Chemotherapy (CVD)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CVD)
Study: 11956264
Drug: Sequential biochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential biochemotherapy
Study: 9607475
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and urokinase (5,000 U boluses at 12 and 24 hours)
Study: 2375296
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (14 g/d, 55% n-3 fatty acids)
Study: 7285484
Drug: d-amphetamine 15
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 15 mg
Study: 704653
Drug: d-amphetamine 5-20
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 5-20 mg
Study: 31382299
Drug: All steroids
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All steroids
Study: 17116511
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing norgestimate (NGM) 180-250 microg and ethinyl estradiol (EE) 35 microg
Study: 15375469
Drug: Surgical valvular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical valvular treatment associated with isolation of the left atrial posterior wall (treated group)
Study: 15375469
Drug: Surgical valvular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical valvular treatment (control group)
Study: 11719726
Drug: Ritonavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (600 mg)
Study: 29133014
Drug: BrECAPP (brentuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: BrECAPP (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 200 mg/m2 on days 2-4, doxorubicin 35 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, procarbazine 100 mg/m2 on days 2-8, and prednisone 40 mg/m2 on days 2-15)
Study: 29133014
Drug: BrECADD (brentuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: BrECADD (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 150 mg/m2 on days 2-4, doxorubicin 40 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, dacarbazine 250 mg/m2 on days 3-4, and dexamethasone 40 mg on days 2-5)
Study: 25415628
Drug: Low-dose succinylcholine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose succinylcholine (0.5 mg/kg)
Study: 25415628
Drug: Low-dose rocuronium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rocuronium with sugammadex (0.25 mg/kg and 0.5 mg/kg respectively)
Study: 17913794
Drug: Trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (160 mg twice daily for 6 days)
Study: 8836757
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose diltiazem (1 mg)
Study: 8836757
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diltiazem (2 or 3 mg)
Study: 1442572
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of isosorbide dinitrate (ISDN)
Study: 1442572
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day of isosorbide dinitrate (ISDN)
Study: 1442572
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of transdermal nitrate
Study: 1442572
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of transdermal nitrate
Study: 30537951
Drug: AOI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOI of 5 L/min oxygen on the non-ventilated lung immediately at the beginning of OLV
Study: 24107257
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of a 3% clodronate solution mixed with Tween-20 at a 1:3 ratio
Study: 24107257
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant procedure (control side)
Study: 24107257
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of a 3% clodronate solution
Study: 14555365
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (enriched stimulus environment, collaborative multidisciplinary interventions, additional yes/no response training)
Study: 14555365
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (standard hospital environment and interventions)
Study: 11099571
Drug: Written oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written oral hygiene instruction
Study: 11099571
Drug: Videotape oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape oral hygiene instruction
Study: 1576626
Drug: Loracarbef 200
Normalized name: loracarbef 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 200 mg once daily for 7 days
Study: 1576626
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg thrice daily for 7 days
Study: 4048810
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen (2 x 50 mg) administered at 7:00 a.m., 1:00 p.m., 7:00 p.m., and 1:00 a.m.
Study: 4048810
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of ketoprofen (5 mg/kg/day) over 24 hours
Study: 11943073
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac sodium
Study: 9522023
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (therapeutic doses)
Study: 7856290
Drug: CFA/II in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFA/II in biodegradable polymer microspheres (BPM), 1 mg administered via intestinal tube on days 0, 7, 14, and 28.
Study: 2796243
Drug: Aminophyllin treatment
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophyllin treatment (oral, therapeutic range 4-10 micrograms/ml)
Study: 2796243
Drug: No aminophyllin
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aminophyllin treatment
Study: 30988133
Drug: Candesartan (AT1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (AT1R receptor antagonist)
Study: 30988133
Drug: C21 (AT2R-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 (AT2R-selective agonist)
Study: 23830306
Drug: Oral tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolerance induction
Study: 23830306
Drug: Triple viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple viral vaccine (MMR)
Study: 22164960
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with maize silage
Study: 22164960
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with grass silage
Study: 22164960
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid supplementation (300 g/d)
Study: 22164960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g/d fumaric acid)
Study: 22164960
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid supplementation (0 g/d, 300 g/d)
Study: 16776791
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy and physical therapy sessions involving home modifications, problem solving, and training in energy conservation, safe performance, balance, muscle strength, and fall recovery techniques.
Study: 16776791
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy and physical therapy intervention
Study: 11562581
Drug: Hypothermic pulsatile
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic pulsatile (n=9, 2.5 L)
Study: 11562581
Drug: Normothermic pulsatile
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic pulsatile (n=8, 2.5 L/min/m2)
Study: 11562581
Drug: Normothermic nonpulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic nonpulsatile (n=12, 2.5 L)
Study: 11562581
Drug: Normothermic nonpulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic nonpulsatile (n=12, 2.8 L)
Study: 11562581
Drug: Hypothermic nonpulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic nonpulsatile (n=11, 2.5 L)
Study: 8201064
Drug: Standard procedures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedures to maintain pharmacotherapy blinds
Study: 3047304
Drug: Sulprostone 500
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulprostone 500 mcg 3 times at 4-hour intervals (regimen 1)
Study: 3047304
Drug: Sulprostone 500
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulprostone 500 mcg every 6 hours for up to 6 injections (regimen 2)
Study: 28952176
Drug: 2% Cryosim‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Cryosim‐1 cream applied twice daily for seven days
Study: 28952176
Drug: Placebo-vehicle cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-vehicle cream applied twice daily for seven days
Study: 28952176
Drug: 2% Cryosim‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Cryosim‐1 cream